F92-24-08

18:28

Fram-pfizer la Jolla

PC25144A

Correction of Inventorship

**2UEP224E3P4V3** 

+8386786233

T-800 7.008/018 F-984

Certificate of Mailing (37 C.F.R. §1.10); I hereby certify that this correspondence is being demosited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 24th day of February 2005

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: SUZANNE BENEDICT, et al.

Serial No.: 10/754,171

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS

AND RADIATION THERAPY

Group Art Unit: 1625

Examiner: AULAKH, CHARANJIT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

## CORRECTION OF INVENTORSHIP IN AN APPLICATION 37 CFR 1.48 (a)

Glaria, Cossed it Thanks Chana Applicant requests to correct the Inventorship in the above-referenced application pursuant to 37 CFR 1.48(a). Inventors Yong Wang and JinJiang Zhu were inadvertently omitted from the Application. This error occurred without deceptive intent.

As requested in 37 CFR 1.48(a), Applicant attaches the following documents:

- 1. A statement from each person being added as an inventor that the error in inventorship occurred without deceptive intention on his part;
- 2. An oath or declaration required by §1.67 (a)(2):
- 3. The processing fee set forth in §1.17(i); and
- 4. The written consent of the assignee set forth in §3.73(b).

If any other fees are due in connection with the filing of this response please charge all necessary fees to the deposit account 500329.

Respectfully submitted,

2/24/05

Reena R. Desai Agent For Applicants Registration No. 53,833

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department

10777 Science Center Drive San Diego, California 92121

Phone: (858) 526-4932 Fax: (858) 678-8233

Page 1 of 1

Feb-24-05

15:30

Freg-plizer la joila

. Licra-billed: 10 10

PC25144A Carrection of Inventorship +6596786233

T-800 P.004/015 F-884

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Mail Stop: Commissioner for Parents, PO Box 1450, Alexandria, VA 22313-1450 on this 2371 day of February 2005.

Rachel Potash

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re the Application of: SUZANNE BENEDICT, et al.

Serial No.: 10/754,171

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTHREOPLASTIC AGENTS

AND RADIATION THERAPY

Group Art Unit: 1625

Examiner: AULAKH, CHARANJIT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

# STATEMENT OF INVENTOR IN AN APPLICATION 37 CFR 1.48 (a)(2)

I, Yong Wang, was inadvertently omitted as an inventor in United States Patent Application No. 10/754,171, filed January 9, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted.

Date: 2/22/2005

Your Wand

F9'=-24-38

15:53

Fraz-pfizer la lolla

+5558738233

2.008/015 F-884

PC25144A Correction of Inventorship

Certificate of Mailing (37 C.F.R. §1 10); I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Commissioner for Potents, PO Box 1450, Alexendria, VA 22313-1450 on this 23rd day of February 2005.

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: SUZANNE BENEDICT, et al.

Serial No.: 10/754,171

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE **EFFICACY OF ANTI-NEOPLASTIC AGENTS** AND RADIATION THERAPY

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1625

Examiner: AULAKH, CHARANJIT

### STATEMENT OF INVENTOR IN AN APPLICATION 37 CFR 1.48 (a)(2)

I, Jinjiang Zhu, was inadvertently omitted as an inventor in United States Patent Application No. 10/754,171, filed January 9, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted.

Jinjiang Zhu

PTO/SB/96 (C9-04)

Approved for use through 07/31/2009, OM9 0651-0031

U.S. Petern and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a colorism of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Agouron Pharmaceuticals, Inc.	
Application NoJ/Patent No.: 10/754,171 Filed/Issue Date: 01/09/2004	
Entitled: Tricyclic Compounds Protein Kinase Inhibitors For Enhancing The Efficacy Of Anti-Neoplastic Agents And Radiation Therapy	
Agouron Pharmaceuticals, Inc. a Consumiton (Name of Assignee) (Type of Assignee, e.g., corpora	ation, partnership, university, government agency, etc.)
states that it is:  1.  the assignee of the entire right, title, and interest; or	
2. an assignee of less than the entire right, title and interest.  The extent (by percentage) of its ownership interest is%	
in the patent application/patent Identified above by virtue of either:	
AP An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 014358 Frame 0202 , or for which a copy OR	
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:	
1. From:To:To:To:To:	
The document was recorded in the United States Patent and Trademark Office at  Reel, Frame, or for which a copy thereof is attached.	
2. From:	
The document was recorded in the United States Patent and Trademark Office at  Reel, Frame or for which a copy thereof is attached.	
3. From:	
The document was recorded in the United States Patent and Trademark Office at  Reel, Frame, or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet.	
Copies of assignments or other documents in the chain of title are attached.  [NOTE: A separate copy (i.e., a true copy of the original assignment document(see Division in accordance with 37 CFR Part 3, if the assignment is to be record MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
	February 16, 2005
· Signature <u>Brvan C. Zielinski</u>	Date
Printed or Typed Name	.858-622-8864
Assistant Secretary	Telephone Number
Title	

This collection of Information is required by 37 GFR 3.73(b). The Information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 GFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, propering, and submitting the complete application form to the USPTO. Time will vary depending upon the Individual case. Any U.S. Patent and Tradement Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.